Arbutus Biopharma Corporation Common Stock (ABUS)
PHARMACEUTICAL PREPARATIONS
Arbutus Biopharma Corporation Common Stock (ABUS) is listed on Nasdaq, where it has traded since July 26, 2007.
- Listed On
- Nasdaq
- Listed Since
- July 26, 2007
- Employees
- 19
- Market Cap
- $961M
About Arbutus Biopharma Corporation Common Stock
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 169 institutions reported holding ABUS, with 140.6 million shares worth $674.8 million in aggregate. The largest reported holder was Two Seas Capital, with 19.1 million shares worth $91.7 million. Of the 5 largest holders listed below, 4 added shares and 1 reduced its position during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Two Seas Capital | 19,095,583 | $92M | Added 2.9% |
| Morgan Stanley | 17,698,305 | $85M | Reduced 31.64% |
| Whitefort Capital Management | 15,794,261 | $76M | Added 5.78% |
| BlackRock | 13,766,071 | $66M | Added 6.16% |
| Vanguard | 9,874,237 | $47M | Added 5.83% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ABUS?
Arbutus Biopharma Corporation Common Stock (ABUS) is listed on Nasdaq, where it has traded since July 26, 2007.
Who are the largest institutional holders of ABUS?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ABUS were Two Seas Capital, Morgan Stanley and Whitefort Capital Management.
How many institutions own ABUS?
169 institutions reported a position in ABUS for the quarter ended June 30, 2026, worth $674.8 million in total.
Did institutions buy or sell ABUS last quarter?
Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter. Every reported holder and its change is on the SentiSense ownership page for ABUS.
Every reported institutional holder, plus insider and congressional trades in ABUS, on SentiSense.